Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Multispecific T-cell-engaging scaffolds are effective anticancer therapies for hematological malignancies.
• There is a need for personalized, multispecific immunotherapeutics that can modulate cancer cell targeting.

Purpose of the Study:

• To develop a modular, split antibody-like approach for personalized T-cell immunotherapy.
• To create a technology enabling T-cell engagement with multiple B-cell antigens.

Main Methods:

• A modular, split antibody-like approach using Fab' fragments and complementary morpholino oligonucleotides (MORFs) was developed.
• The technology, named multiantigen T-cell hybridizers (MATCH), utilizes Watson-Crick base pairing for self-assembly.
• Cancer-specific T-cell recruitment was achieved against CD20, CD38, BCMA, and SLAMF7 targets.

Main Results:

• MATCH demonstrated cell-specific T-cell activation against lymphoma, leukemia, and multiple myeloma cell lines in vitro.
• Modular T-cell rechallenge against three different cancers was achieved using MATCH.
• In vivo studies showed long-term survival in non-Hodgkin's lymphoma xenograft models with CD20-directed MATCH therapy.
• Optimal T-cell-to-target cell ratios were identified for disease onset delay in a second in vivo model.

Conclusions:

• MATCH is a versatile and modular platform for developing personalized T-cell immunotherapeutics.
• The technology shows promise for treating hematological malignancies by enabling adaptable and multispecific T-cell engagement.
• MATCH offers a novel strategy for enhancing T-cell-mediated anticancer activity.